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Background. Low-Risk Human Papillomavirus (LR-HPV) genotypes 6 and 11 cause genital warts. This study investigated the
associationofLR-HPVinfectionwithmalecircumcision(MC).Methods.WeuseddatafromtheSouthAfricanMCtrialconducted
among young men. Urethral swabs, collected among intervention (circumcised) and control (uncircumcised) groups, were
analyzed using HPV linear array. Adjusted LR-HPV prevalence rate ratio (aPPR) and Poisson mean ratio (aPMR) of number of
LR-HPV genotypes were estimated using log-Poisson regression, controlling for background characteristics, sexual behaviour, and
HIV and HSV-2 statuses. Results. Compared to controls, LR-HPV prevalence and mean number of genotypes were signiﬁcantly
lower among the intervention group ((8.5% versus 15.8%; aPRR: 0.54, P<. 001) and (0.33 versus 0.18; aPMR: 0.54, P<. 001),
resp.). Mean number of LR-HPV genotypes increased with number of lifetime sexual partners and decreased with education level
and consistent condom use. Conclusions. This study shows a reduction in LR-HPV infection among circumcised men.
1.Introduction
Human Papillomavirus (HPV), a small DNA virus, is the
most common sexually transmitted infection in the world.
HPV prevalence in Africa is disproportionably high, ranging
from 22.1% to 46.0% among women [1–3]. More than 100
HPV genotypes have been identiﬁed, of which about 40
infect the mucosal epithelium. They are divided into “high-
risk” and “low-risk” genotypes on the basis of their associ-
ation with malignant lesions of the cervix. High-risk HPV
(HR-HPV) infection has been linked with genital cancer [4–
6].
Low-risk HPV (LR-HPV) genotypes 6 and 11 cause
around 90% of genital warts (GWs), also called condylomata
acuminate [7]. In Sub-Saharan Africa, LR-HPV prevalence
hasbeenestimatedat13.6%[2],rangingfrom1.2%to30.0%
depending on geographical region, target population, and
sexual behaviour [3]. Although treatment helps to eliminate
the virus, GWs are often painful, and new lesions or recur-
rences are frequent, resulting in patient dissatisfaction and
leading to psychological distress [7, 8]. GWs are associated
with a signiﬁcant decline in health-related quality of life [9].
A study assessing the psychological burden of HPV-related
diseases found that GWs had the largest impact on quality of2 Infectious Diseases in Obstetrics and Gynecology
life compared with other clinical forms, chieﬂy due to their
impact on sexuality, self-image, and partner transmission
[10].
There is evidence that multiple HPV infection may
have important clinical and epidemiological implications.
Infection with multiple HPV genotypes has been associated
withconcurrentanogenitalwarts[11–13],acquisitionofnew
HPVtypeandHPVinfectionpersistence[14],dysplasia[15],
cervicalintraepithelialneoplasiaseverity[16,17],cytological
abnormalities in anal specimens [18], and HIV coinfection
[19–21].
Hence, the analysis of LR-HPV infection in terms of
number of LR-HPV genotypes detected in urethral swabs is
important since being infected with one genotype may be
diﬀerent from being infected with two or more genotypes.
Ar e c e n to b s e r v a t i o n a ls t u d yh a ss u g g e s t e dt h a tH P V
prevalence was reduced among circumcised men compared
to uncircumcised men [22], whereas other studies failed
to ﬁnd an association [23, 24]. However, two recent male
circumcision (MC) trials have demonstrated a lower HR-
HPVprevalenceandincidenceamongcircumcisedmen[25–
27]. This protective eﬀect could be explained by the role
of the foreskin on HPV transmission [28]. Consequently,
the same protective eﬀect of MC can be expected on LR-
HPV prevalence, but to date, very little is known about this
association.
T h ep r i m a r yo b j e c t i v eo ft h i ss t u d yw a st oi n v e s t i g a t e
the eﬀect of MC on LR-HPV infection by considering both
LR-HPV prevalence and the number of LR-HPV genotypes
detected among young men. The secondary objective was to
identify other risk factors of LR-HPV infection. Data used
were collected during the MC randomized controlled trial
(RCT) conducted in Orange Farm (South Africa), which
demonstrated a partially protective eﬀect of MC on the
acquisition of HIV [29].
2. Methods
2.1. Collection of Data. Technical details of the Orange Farm
MC RCT (ANRS-1265) have been published elsewhere [29].
The trial took place in Orange Farm, a semiurban township
neighbouring the city of Johannesburg, between February
2002 and July 2004. A total of 3274 uncircumcised men,
aged 18 to 24, were recruited from the general population.
They were randomly assigned to be either immediately
circumcised (intervention group) or to undergo circumci-
sion after the end of the trial (control group) and were
followed up for 21 months. During each of the four visits
(at baseline and follow-up visits at months 3, 12, and 21),
circumcisionstatuswasassessedbyatrainednurseviagenital
examination, blood samples were obtained and tested for
HIV as well as HSV-2, and a face-to-face questionnaire was
administered.
The current study uses data collected during the 21-
month visit. Participants were included in the trial regardless
of their HIV and HSV-2 status. The sample includes all
the men, among the trial participants, who reported for
the 21-month follow-up visit between March 7th, 2005 and
November 24th, 2005, and among whom urethral swabs
were collected during this period. The selection has been
described in further details in a previous publication [25].
Five hundred and ninety six follow-up visits were added
to the original database analyzed to report results on the
association between MC status and HR-HPV [25], yielding
a total of 1768 follow-up visits. One urethral swab was
collected by the same nurse from each participant and
tested for HPV. All participants signed a written consent
form for this test to be performed. The collection of swabs
could not be started earlier because of limited funding.
Swabs were analyzed to assess the association between MC
and both prevalence and number of LR-HPV genotypes.
The 21-month questionnaire allowed for data collection
on background characteristics (age, ethnic group, level of
education, number of lifetime sexual partners, and marital
status) as well as reported sexual behaviour in the past
12 months (number of sexual contacts and frequency of
condom use).
2.2. Laboratory Methods. Detailed laboratory methods for
HIV-1 and HSV-2 testing have previously been reported
[29, 30]. Urethral swabs were frozen at −20
◦C immediately
after collection and kept frozen until processing. DNA was
extracted from the specimens using the MagNA Pure LC
(Roche) instrument, with the Roche MagNA Pure LC DNA
I Isolation Kit. Swabs were lysed in 500μL of the kit lysis
buﬀer for 30 minutes at room temperature. The MagNa Pure
external lysis protocol was used to extract DNA from the
lysis buﬀer into a 100μLe l u a t e .5 0μL of the eluate was used
for screening (Roche Amplicor HPV test), and the other
50μL eluate was used for genotyping (Roche Linear Array
Genotyping test). This standardized PCR-based method can
detect37genotypesofHPV[31,32].Fifteenresults(15/1768;
0.84%) with a negative internal beta globin PCR control
were excluded, four in the control arm (4/867; 0.46%) and
eleven in the intervention arm (11/901; 1.2%). All positives
were genotyped. An LR-HPV-positive sample was deﬁned
as a sample where at least one LR-HPV genotype was
detected.
2.3. Data Analysis. Roche Linear Array Genotyping test was
used to detect 23 HPV genotypes which are classiﬁed as
nononcogenic.Inthispaper,allofthefollowing23genotypes
are characterized as LR-HPV: 6, 11, 26, 40, 42, 53, 54, 55, 61,
62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, and CP6108.
A more conservative approach was used, which considered a
subset of 11 genotypes (i.e., genotypes: 6, 11, 26, 40, 42, 53,
54, 55, 83, 84, CP6108), excluding any genotype having been
labelled as of intermediate risk in the literature or not listed
in the LR-HPV genotypes list [5, 33–35].
We used multivariate log-Poisson regression to analyze
both LR-HPV positivity and number of LR-HPV genotypes
detectedforeachparticipant.Resultsareformulatedinterms
of prevalence rate ratios (PRRs) of LR-HPV positivity and
Poisson mean ratio (PMRs) of the mean number of LR-HPV
genotypes, respectively, comparing men of the intervention
group with men of the control group. The intention-to-
treat (ITT) and as-treated (AT) adjusted PRRs (aPRRs) andInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Background characteristics, reported sexual behaviour, and HIV, HSV-2 and low-risk HPV prevalence of the study population.
Control
N = 863
Intervention
N = 890 P (1)
Background Characteristics
Ethnic group (%)
Sotho
Zulu
Other
53.2
33.1
13.7
54.2
28.3
17.5
.02
Lives with a partner (%) (2) 4.7 5.5 .61
Aged 21 and older (%) 50.1 55.1 .04
Primary level of education completed (%) 98.8 (98.0) .18
Reported sexual behaviour
Mean (median) number of lifetime partners 4.3 (4.0) 4.4 (4.0) .33
Had at least one sexual partnership in the past 12 months (%) 71.2 77.9 .004
Mean (median) number of partnerships in the past 12 months (2) 1.4 (1.0) 1.3 (1.0) .70
Mean (median) number of sexual intercourses in the past 12 months (2) 13.3 (5.0) 13.9 (6.0) .41
Consistent condom use in the past 12 months (%) (2) 23.6 24.9 .70
Sexually transmitted infection prevalence at the 21-month visit
HIV positive (%) 7.2 4.6 .03
HSV-2 positive (%) 8.6 10.6 .17
Low-risk HPV positive (23 genotypes) (%) 15.8 (n = 136) 8.5 (n = 76) <.001
Low-risk HPV positive (11 genotypes) (%) 12.4 (n = 107) 6.6 (n = 59) <.001
(1) Fisher’s exact for percentage comparison and Mann-Whitney test for mean comparison;
(2) among those having at least one sexual intercourse in the past 12 months (437 control and 497 intervention participants).
PMRs (aPMRs) were estimated controlling for the following
covariates: ethnic group, age, education, number of lifetime
sexual partners, condom use in the past 12 months, as well
as HIV and HSV2 statuses at the 21-month visit. Analyses
were repeated using as an outcome the subset of 11 LR-
HPV genotypes. Because HIV is reduced by MC and is
associatedwithHPVinfection [36],weassessedthepotential
impact of HIV acquisition on the results by excluding those
whoHIVseroconvertedduringthefollow-upperiod.Finally,
to evaluate the eﬀect of a possible imbalance between the
groups,analyseswererepeatedusingpropensityscorescoded
in quintiles [37]. Percentages were compared with Fisher’s
exact test and means with the Mann-Whitney test. Statistical
analyses were performed using STATA 9.0 (StataCorp. 2005.
Stata Statistical Software: Release 9. College Station, TX:
StataCorp LP).
2.4. Ethics. The trial was conducted with the understanding
and the written consent of all participants. The research
protocol was reviewed and approved by the University
of the Witwatersrand Human Research Ethics Committee
(Medical) on February 22nd, 2002 (protocol study no.
M020104). The trial was also approved by the Scientiﬁc
Commission of the French National Agency for AIDS
Research (ANRS; protocol study no. 1265; 2002, decision
no. 50), and authorization was obtained from the City of
Johannesburg, Region 11, on 25 February 2002. This trial
h a sb e e nr e g i s t e r e da thttp://www.clinicaltrials.gov/ under
the number NCT00122525.
3. Results
The 1753 participants from whom a urethral swab was
collectedatthe21-monthvisitandanalysedwereincludedin
the analysis. The mean (median) durations in days of follow-
upamongtheinterventionandcontrolgroupwere653(637)
and 648 (637), respectively.
Table 1 reports the study population’s baseline charac-
teristics, reported sexual behaviour and HIV, HSV-2, and
LR-HPV prevalences at the 21-month visit. Median age
was 21.2 years (mean: 21.2, 95%CI: 21.2–21.3). The most
frequent sexually transmitted infection (STI) was LR-HPV.
Compared to control group participants, men from the
intervention group were slightly older (mean: 21.3 versus
21.1, P = .04) and reported more frequently having had
a sexual partnership in the last year. Level of education,
living with a partner, number of lifetime sexual partners,
and consistent condom use were not statistically diﬀerent
betweenthetwogroups.HIVandLR-HPVprevalencesatthe
21-month visit were signiﬁcantly lower in the intervention
group in comparison with the control group. The mean
number of LR-HPV genotypes was 0.25 (95%CI: 0.21–0.30).
The number of HR-HPV and LR-HPV genotypes were
correlated (ρ = 0.67, P<. 001). Among HR-HPV-infected
men, 56.2% (95%CI: 50.7–61.6) were infected with LR-
HPV. Among LR-HPV-infected men, 85.9% (95%CI: 81.1–
90.6) were infected with HR-HPV. Figure 1 indicates that the
percentage of each of the 23 LR-HPV genotypes was always
lower among men from the intervention group compared to4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Intention-to-treat (ITT) and As-treated (AT) Poisson Mean Ratios (PMRs) of the number of low-risk HPV (LR-HPV) genotypes
among the 1753 participants.
Number of
participants (LR-HPV
infected)
Mean of
LR-HPV
genotypes
PMR (95% CI) ITT aPMR (1)
(95% CI)
AT aPMR (1)
(95% CI)
Circumcision status
Randomization group
Control
Intervention
863 (136)
890 (76)
0.33
0.18
1
0.53 (0.44–0.64)
P<. 001
1
0.54 (0.44–0.66)
P<. 001
not applicable
Circumcision status
Uncircumcised
Circumcised
855 (136)
898 (76)
0.35
0.16
1
0.45 (0.37–0.55)
P<. 001
not applicable
1
0.46 (0.37–0.56)
P<. 001
Background characteristics
Ethnic group
Sotho
Zulu
Other
941 (116)
538 (66)
274 (30)
0.24
0.27
0.26
1
1.12 (0.91–1.37)
P = .29
1.05 (0.80–1.37)
P = .75
1
1.05 (0.86–1.30)
P = .63
1.00 (0.76–1.30)
P = .98
1
1.04 (0.84–1.28)
P = .77
1.06 (0.81–1.39)
P = .56
Age
Under 21
21 and older
831 (82)
922 (130)
0.20
0.30
1
1.53 (1.26–1.85)
P<. 001
1
1.08 (0.88–1.32)
P = .48
1
1.10 (0.90–1.35)
P = .27
Primary level of education
Uncompleted
Completed
28 (6)
1725 (206)
0.54
0.25
1
0.47 (0.28–0.78)
P = .004
1
0.50 (0.30–0.84)
P = .009
1
0.48 (0.29–0.81)
P = .006
Reported sexual behaviour
Number of lifetime sexual partners
two or less
more than two
586 (49)
1167 (163)
0.14
0.31
1
2.24 (1.76–2.84)
P<. 001
1
1.68 (1.30–2.16)
P<. 001
1
1.69 (1.31–2.18)
P<. 001
Condom use in the past 12 months(2)
Inconsistent
Consistent
695 (99)
223 (19)
0.32
0.15
1
0.48 (0.33–0.68)
P<. 001
1
0.66 (0.46–0.95)
P = .03
1
0.68 (0.47–0.99)
P = .04
Sexually transmitted infection prevalence
at the 21-month visit
HIV
negative
positive
1650 (175)
103 (37)
0.21
1.05
1
5.10 (4.11−6.34)
P<. 001
1
3.29 (2.57–4.22)
P<. 001
1
3.20 (2.49–4.10)
P<. 001
HSV-2
negative
positive
1585 (173)
168 (39)
0.22
0.59
1
2.68 (2.15−3.36)
P<. 001
1
1.49 (1.15–1.93)
P = .002
1
1.52 (1.17–1.96)
P = .002
(1) Adjusted for ethnic group, age, education, number of lifetime sexual partners, condom use in the past 12 months, and HIV and HSV2 statuses at the 21-
month visit;
(2) among those having at least one sexual intercourse in the past 12 months.
men from the control group. In the ITT comparison, the
diﬀerence was signiﬁcant for genotypes 40, 42, 53, 70, 84,
and CP6108. Among the 212 LR-HPV-infected men, 51.4%
(95%CI: 44.6–58.2) were infected with more than one LR-
HPV genotype, for a maximum of 11 genotypes. Figure 2
shows the distribution of the number of LR-HPV genotypes
among LR-HPV-infected participants.
3.1. Risk Factors for Urethral LR-HPV Infection. The preva-
lence of LR-HPV infection was signiﬁcantly lower among
intervention group participants compared to control group
participants (8.5% versus 15.8%; ITT aPRR: 0.54, 95%CI:
0.41–0.72, P<. 001 and AT aPRR: 0.53, 95%CI: 0.40–0.70,
P<. 001).
Table 2 shows the univariate and multivariate PMRs of
thenumberofLR-HPVgenotypesbyMCstatusatthesched-
uled 21-month visit. In both univariate and multivariate ITT
and AT analyses, the mean number of LR-HPV genotypes
in the intervention group was signiﬁcantly lower, about
half that of the control group. The association was slightly
stronger in the AT analyses.
Results remained unchanged when the more restrictive
deﬁnition of 11 LR-HPV genotypes was considered, with a
twofold decrease of the mean number of LR-HPV in the
intervention group compared with the control group (0.10
versus 0.21; ITT aPMR: 0.51, 95%CI: 0.39−0.66, P<. 001).
Mean number of LR-HPV genotypes signiﬁcantly
increased with the number of lifetime sexual partners (ITTInfectious Diseases in Obstetrics and Gynecology 5
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Figure 1: Distribution of the low-risk HPV genotypes as a function
of randomization group among the 1753 participants (intention to
treat population).
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Figure 2: Distribution of the number of low-risk HPV genotypes
collected in each urethral swabs as a function of randomization
group among the 1753 participants (intention to treat popula-
tion).
aPMR: 1.05, 95%CI: 1.02–1.09, P = .001). Prevalent HIV
and HSV-2 infections at the 21-month visit were associated
with an increased number of LR-HPV genotypes (ITT
aPMR: 3.40, 95%CI: 2.65–4.36, P<. 001 and ITT aPMR:
1.49, 95%CI: 1.15–1.92, P = .002, resp.). Conversely, mean
number of LR-HPV genotypes was lower for participants
havingcompletedtheprimarylevelofeducation(ITTaPMR:
0.47, 95%CI: 0.28–0.79, P = .004) and those reporting
consistent condom use (ITT aPMR: 0.65, 95%CI: 0.45–0.93,
P = .02).
When participants who HIV seroconverted during
follow-up (n = 33) were excluded from the analyses, the
eﬀect of MC on number of LR-HPV remained unchanged
(ITT aPMR: 0.53, 95%CI: 0.43–0.65, P<. 001, and AT
aPMR: 0.47, 95%CI: 0.38–0.58, P<. 001). This implies that
the eﬀect of MC on LR-HPV is independent of the eﬀect of
MC on HIV.
The aPMRs were almost identical when the analyses were
adjusted for the propensity score in addition to the other
covariates (ITT aPMR: 0.55, 95%CI: 0.45–0.66, P<. 001,
and AT aPMR: 0.46, 95%CI: 0.38–0.57, P<. 001). This
suggests that a possible imbalance between groups due to a
diﬀerential follow-up had no eﬀect on the association of LR-
HPV infection with MC.
4. Discussion
Using data collected during the MC trial conducted in
Orange Farm (South Africa), we found a strong independent
associationbetweenLR-HPVurethralinfectionandMC.LR-
HPV infection was analysed as a prevalence rate and in terms
of number of LR-HPV detected in urethral swabs, because it
was assumed that being infected with one genotype was dif-
ferent from being infected with two or more genotypes [12,
13, 20]. It was found that both risks of being infected with
oneLR -HPVgenotype(PMR)andwithatleastonegenotype
(PPR) were consistently decreased among men from the
circumcised group. These men did not diﬀer signiﬁcantly
fromcontrolgroupparticipantsintermsofsexualbehaviour,
apart from reporting more frequently at the 21-month visit
having had at least one sexual partnership in the past 12
months.
The mechanisms by which circumcised men are less
likely to be infected with HPV could be due to a reduced
acquisition of new infection or an increased clearance
of pre-existing infection, because the absence of foreskin
may reduce the risk of autoreinfection at the urethral site
[28].
This study has some limitations, primarily the lack of
data on HPV status at baseline, so the causality of MC on
reduced LR-HPV infection cannot be rigorously demon-
strated. However, MC was randomly assigned, and control-
ling for the propensity score didnot aﬀect the results. A
second limitation is that participants were not blinded, so
they might have changed their sexual behaviour according to
their randomization group. Lastly, detection of LR-HPV was
performedonurethralswabs,whichareknowntomissinfec-
tions compared with detection in the glans, corona sulcus, or
penile shaft [38, 39]. Thus, the prevalence of LR-HPV in our
cohort may be underestimated, but such underestimation
would be equally distributed among the two groups of ran-
domization. Hence, its impact on PMR is likely to be small,
anddespitethispotentiallossofpower,ourresultsevidenced
a signiﬁcant protective eﬀect of MC on urethral LR-HPV
infection.
To date, little was known on the association of MC
with LR-HPV. Few observational studies have studied this
association but results remained inconsistent [22, 23, 40,
41]. However, Tobian and colleagues [27] have recently
published results similar to those of this study, analyzing
data collected in another African population and using
ad i ﬀerent HPV swabbing site. They reported a 44%
reduction in LR-HPV prevalence among circumcised men.
Hence, we can conclude that the protective eﬀect of MC
on HR-HPV infection can be generalized to LR-HPV
genotypes.
In accordance with observational studies, our study
reveals some other risk factors of LR-HPV, such as the
number of lifetime sexual partners [22–24, 42, 43] and being
older than 21 years old [14], although the role of age may
vary [22, 43]. Lastly, our results bring evidence supporting
the protective role of condom use on HPV and LR-HPV
infections [14, 23, 40, 43].6 Infectious Diseases in Obstetrics and Gynecology
5. Conclusion
MC, an immediately available and cost-eﬀective method,
was proven to reduce HR-HPV infection [25, 27]. Hence
the protective eﬀe c to fM Co nL R - H P V ,d e m o n s t r a t e di n
this study, provides new arguments endorsing the WHO-
UNAIDS recommendation for the implementation of MC
programs in targeted countries [44].
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